7.99 USD
▲+0.04+11.75%
盘后 7.00 -2.05%
2026-08-03
市值
$493.40M
市盈率
—
EPS
-1.34
股息率
—
52 周区间
4.50 – 10.06
成交量
1.71M
Beta
3.38
目标价
26.20
52W 低 4.5052W 高 10.06
价格走势
公司简介
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; a...